Hamadan University of Medical Sciences Brucellosis Research Center

Principal Investigator: Fariba Keramat

  • -Professor of Tropical and Infectious Diseases
  • -Hamadan University of Medical Sciences
  • -Director, Brucellosis Research Center


Autumn 2014

Stage1: • To determination of brucellosis seroprevalence in Famenin populations. • To Identification and prioritization of risk factors. Stage2: • To determination the seroprevalence of brucellosis in the livestock population. • To identification of human and livestock species • To determine Antibiotic resistance. • To study the Prevalence of microbial contamination of dairy products. • To determine the pattern of disease transmission. • To Intervention to control, reduce, and prevent. Stage 3: • To evaluation of implementer intervention on brucellosis incidence.

Urban and rural population and livestock in Famenin city ,Hamadan province ,Iran

Two stage sampling (clusters were selected using systematic sampling) in Famenin city population for serologic investigation in 3161 persons were used. All cases of brucellosis will enroll in the study All brucellosis cases, infected livestock and dairy products in Famenin city will investigate

The data in this study will be collected in three phases: Phase 1: Research was conducted to determine the serological status of human contamination and to identify and prioritize risk factors, and to record all cases of brucellosis. phase 2: In patients: clinical symptoms, transmission pattern, complications and recurrence, diagnostic and treatment methods, drug resistance will investigate. Investigations will be carried out to determine the serological status of livestock contamination. Educational interventions and vaccination of livestock will be done. Phase 3: Monitoring and intervention studies

Monitoring the clinical signs and seroprevalence of brucellosis in humans and livestock populations studied in Famenin during the study period.

brucellosis Risk factors

Evaluation of subclinical and chronic brucellosis, relapse, complications, and drug resistance in the patients with brucellosis

Part Cohort